Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A bioequivalence study of vinorelbine tartrate injectable emulsion (ANX-530) in patients with advanced cancer.

Next Previous
X
Search
Trial Profile

A bioequivalence study of vinorelbine tartrate injectable emulsion (ANX-530) in patients with advanced cancer.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vinorelbine (Primary)
  • Indications Breast cancer; Cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Mast Therapeutics

    • Most Recent Events

    • 14 Mar 2013 Additional lead trial centres identified as reported by ClinicalTrials.gov.
    • 09 Aug 2011 The FDA reports in a Complete Response Letter that the results may not be valid and that this trial will need to be repeated.
    • 20 Jan 2011 The FDA established a Prescription Drug User Fee Act (PDUFA) date of September 1, 2011 for the review of the Exelbine (ANX-530) NDA, acording to an Adventrix media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top